IL289919B2 - Long-chain functional mono- and dicarboxylic acids, useful for the prevention or treatment of diseases - Google Patents
Long-chain functional mono- and dicarboxylic acids, useful for the prevention or treatment of diseasesInfo
- Publication number
- IL289919B2 IL289919B2 IL289919A IL28991922A IL289919B2 IL 289919 B2 IL289919 B2 IL 289919B2 IL 289919 A IL289919 A IL 289919A IL 28991922 A IL28991922 A IL 28991922A IL 289919 B2 IL289919 B2 IL 289919B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- solvate
- pharmaceutically acceptable
- treating
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/34—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings containing more than one carboxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/39—Unsaturated compounds containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878852P | 2019-07-26 | 2019-07-26 | |
| US201962901739P | 2019-09-17 | 2019-09-17 | |
| PCT/US2020/043274 WO2021021563A1 (en) | 2019-07-26 | 2020-07-23 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL289919A IL289919A (en) | 2022-03-01 |
| IL289919B1 IL289919B1 (en) | 2025-06-01 |
| IL289919B2 true IL289919B2 (en) | 2025-10-01 |
Family
ID=74189909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289919A IL289919B2 (en) | 2019-07-26 | 2020-07-23 | Long-chain functional mono- and dicarboxylic acids, useful for the prevention or treatment of diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US11098002B2 (enExample) |
| EP (2) | EP4003314B1 (enExample) |
| JP (2) | JP7783802B2 (enExample) |
| KR (1) | KR20220039754A (enExample) |
| CN (2) | CN118903087A (enExample) |
| AU (2) | AU2020321945B2 (enExample) |
| BR (1) | BR112022000993A2 (enExample) |
| CA (1) | CA3143294C (enExample) |
| ES (1) | ES2991100T3 (enExample) |
| IL (1) | IL289919B2 (enExample) |
| MX (2) | MX2022000570A (enExample) |
| TW (2) | TW202532387A (enExample) |
| WO (1) | WO2021021563A1 (enExample) |
| ZA (1) | ZA202110502B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11098002B2 (en) | 2019-07-26 | 2021-08-24 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease |
| HUE071473T2 (hu) * | 2020-04-15 | 2025-09-28 | Medivir Ab | MIV-818/lenvatinib kombinációs terápia májrák kezelésére |
| WO2022159811A1 (en) * | 2021-01-25 | 2022-07-28 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease |
| CA3209453A1 (en) | 2021-01-25 | 2022-07-28 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease |
| CA3203644A1 (en) * | 2021-02-26 | 2022-09-01 | Obi Pharma, Inc. | Use of akr1c3-activated compound |
| KR20240004519A (ko) * | 2021-04-28 | 2024-01-11 | 아센타위츠 파마슈티컬즈 리미티드 | 면역관문 억제제와 함께 akr1c3-활성화 화합물을 사용하는 병용 요법 |
| CN115887435A (zh) * | 2021-09-23 | 2023-04-04 | 博骥源（上海）生物医药有限公司 | 长链类化合物及其用途 |
| CN114736191B (zh) * | 2022-04-01 | 2023-08-08 | 上海工程技术大学 | 特普替尼中间体及其制备方法和应用 |
| CN114949230B (zh) * | 2022-06-13 | 2024-12-06 | 厦门大学附属第一医院 | 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用 |
| CN115844887B (zh) * | 2022-12-28 | 2023-09-08 | 中国人民解放军空军军医大学 | Selonsertib在制备治疗癌症的药物中的用途 |
| KR102928747B1 (ko) | 2023-07-21 | 2026-02-26 | 대한민국 | 피라졸로[1,5-에이]퀴나졸린 유도체 화합물을 포함하는 인간면역결핍바이러스 억제용 조성물 |
| CN117843938B (zh) * | 2024-03-08 | 2024-05-24 | 华东理工大学 | 一种类聚烯烃的长碳链聚酯弹性体、制备方法及其应用 |
| CN120131672B (zh) * | 2025-04-28 | 2025-12-26 | 山东大学 | 乐伐替尼联合熊去氧胆酸在肝癌治疗中的应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US397037A (en) | 1889-01-29 | Conductor-support | ||
| US2789970A (en) | 1953-12-08 | 1957-04-23 | Eastman Kodak Co | Polycarbonates from 1, 4-bis-(beta-hydroxyethyl)-benzenes-bis |
| GB900875A (en) | 1959-11-12 | 1962-07-11 | Sierra Eng Co | Check valve |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2410782C2 (de) | 1974-03-07 | 1982-02-18 | Dynamit Nobel Ag, 5210 Troisdorf | Phenylendiessigsäuredialkylester und Verfahren zu deren Herstellung |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| IL64542A0 (en) * | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5387672A (en) * | 1993-03-02 | 1995-02-07 | The University Of Maryland At Baltimore | Hemoglobin intramolecularly cross-linked withlong chain divalent reagents |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US20020037876A1 (en) * | 1998-06-25 | 2002-03-28 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| CA2425311C (en) | 2000-10-11 | 2011-06-14 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| JP2004531459A (ja) | 2000-10-11 | 2004-10-14 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用 |
| JP2005522504A (ja) | 2002-04-10 | 2005-07-28 | エスペリオン セラピューティクス，インコーポレイテッド | パントラクトンおよびパントテン酸誘導体を含むアシル補酵素−ａのミミック、その組成物、ならびにコレステロール管理の方法および関連の使用 |
| ES2625429T3 (es) | 2003-01-23 | 2017-07-19 | Esperion Therapeutics Inc. | Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes |
| US7638531B2 (en) | 2005-12-21 | 2009-12-29 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists |
| SG189019A1 (en) | 2010-10-18 | 2013-05-31 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
| CN105997967B (zh) | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
| CN107096032A (zh) | 2011-05-16 | 2017-08-29 | 罗马克实验室有限公司 | 在有需要的对象中刺激免疫应答的方法 |
| WO2012159107A1 (en) | 2011-05-19 | 2012-11-22 | Rhode Island Hospital | Inhibition of renal fibrosis |
| US20140378922A1 (en) | 2013-06-25 | 2014-12-25 | Basf Se | Fluid-absorbent article with indicator |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| CN105801405A (zh) | 2016-05-23 | 2016-07-27 | 天津迪尔斯化学科技有限公司 | 一种降血脂小分子化合物、中间体及各自制备方法 |
| US10004761B2 (en) | 2016-06-21 | 2018-06-26 | Mark M. Levy | Malodor neutralizing composition |
| CN110200981A (zh) | 2019-06-06 | 2019-09-06 | 中国药科大学 | 五环三萜皂苷的医药用途及其药物组合物 |
| US11098002B2 (en) | 2019-07-26 | 2021-08-24 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease |
| WO2022159811A1 (en) | 2021-01-25 | 2022-07-28 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease |
| CA3209453A1 (en) | 2021-01-25 | 2022-07-28 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease |
-
2020
- 2020-07-23 US US16/937,154 patent/US11098002B2/en active Active
- 2020-07-23 EP EP20848591.2A patent/EP4003314B1/en active Active
- 2020-07-23 TW TW113140056A patent/TW202532387A/zh unknown
- 2020-07-23 AU AU2020321945A patent/AU2020321945B2/en active Active
- 2020-07-23 ES ES20848591T patent/ES2991100T3/es active Active
- 2020-07-23 WO PCT/US2020/043274 patent/WO2021021563A1/en not_active Ceased
- 2020-07-23 IL IL289919A patent/IL289919B2/en unknown
- 2020-07-23 JP JP2022503935A patent/JP7783802B2/ja active Active
- 2020-07-23 TW TW109124977A patent/TWI862642B/zh active
- 2020-07-23 BR BR112022000993A patent/BR112022000993A2/pt unknown
- 2020-07-23 CA CA3143294A patent/CA3143294C/en active Active
- 2020-07-23 EP EP24186245.7A patent/EP4464688A1/en active Pending
- 2020-07-23 CN CN202410969586.6A patent/CN118903087A/zh active Pending
- 2020-07-23 MX MX2022000570A patent/MX2022000570A/es unknown
- 2020-07-23 KR KR1020227005523A patent/KR20220039754A/ko active Pending
- 2020-07-23 CN CN202080052472.5A patent/CN114126593B/zh active Active
-
2021
- 2021-03-03 US US17/190,844 patent/US11084773B1/en active Active
- 2021-04-26 US US17/240,513 patent/US11267778B2/en active Active
- 2021-07-12 US US17/373,110 patent/US20220402851A1/en not_active Abandoned
- 2021-12-15 ZA ZA2021/10502A patent/ZA202110502B/en unknown
-
2022
- 2022-01-07 US US17/571,107 patent/US20230007838A1/en not_active Abandoned
- 2022-01-13 MX MX2025002978A patent/MX2025002978A/es unknown
-
2023
- 2023-06-01 US US18/204,442 patent/US12180151B2/en active Active
-
2024
- 2024-08-22 US US18/812,284 patent/US12252467B2/en active Active
-
2025
- 2025-03-07 AU AU2025201689A patent/AU2025201689A1/en active Pending
- 2025-03-17 US US19/082,112 patent/US20250367149A1/en active Pending
- 2025-11-28 JP JP2025207487A patent/JP2026048714A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| CAS 137334-84-0, CAS 137334-84-0, 15 November 1991 (1991-11-15) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289919B2 (en) | Long-chain functional mono- and dicarboxylic acids, useful for the prevention or treatment of diseases | |
| Maeda | The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting | |
| Coradini et al. | Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But | |
| Vong et al. | Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer | |
| Orrù et al. | Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis | |
| JP2022542238A5 (enExample) | ||
| Wu et al. | Efficient and targeted chemo-gene delivery with self-assembled fluoro-nanoparticles for liver fibrosis therapy and recurrence | |
| Jia et al. | Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro | |
| Lee et al. | Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate | |
| Zhao et al. | Chitooligosaccharide supplementation prevents the development of high fat diet-induced non-alcoholic fatty liver disease (NAFLD) in mice via the inhibition of cluster of differentiation 36 (CD36) | |
| Makita et al. | Anti-tumor activity of KNTC2 siRNA in orthotopic tumor model mice of hepatocellular carcinoma | |
| EP3676256B1 (en) | Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer | |
| Velázquez et al. | The scientific rationale and clinical application of short-chain fatty acids and medium-chain triacylglycerols | |
| CA3238116A1 (en) | Combination of antibody-drug conjugate and parp1 selective inhibitor | |
| Shin et al. | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | |
| Tanaka et al. | In vivo evaluation of irinotecan-loaded QuadraSphere microspheres for use in chemoembolization of VX2 liver tumors | |
| CN112826796B (zh) | 一种纳米粒在制备治疗胆囊相关疾病的药物中的应用 | |
| Sun et al. | Multifunctional poly (amino acid) nanomedicine modulates macrophage polarization for osteosarcoma immunotherapy | |
| KR20080091824A (ko) | 메글리티니드류를 함유하는 간 섬유화 예방용 의약 조성물 | |
| Wang et al. | Targeted depletion of intratumoral bacteria using PEGylated metronidazole to augment cancer treatment efficacy | |
| CN114430756B (zh) | 担载短链脂肪酸酯的亲水-疏水性共聚物 | |
| Bae et al. | Enhanced anti-cancer effect of 5-fluorouracil loaded into thermo-responsive conjugated linoleic acid-incorporated poloxamer hydrogel on metastatic colon cancer models | |
| Nishi et al. | Improved stomach selectivity of gene expression following microinstillation of plasmid DNA onto the gastric serosal surface in mice | |
| Pavlek et al. | Case report: Urgent liver pathologies: All in one | |
| Jia et al. | A superoxide anion radical-activatable Golgi-targeting prodrug-based albumin complex for synergistic chemo-immunotherapy of triple-negative breast cancer |